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https://doi.org/10.1016/j.cell.2020.08.026SUMMARYThe coronavirus disease 2019 pandemic has made deployment of an effective vaccine a global health prior-
ity. We evaluated the protective activity of a chimpanzee adenovirus-vectored vaccine encoding a prefusion
stabilized spike protein (ChAd-SARS-CoV-2-S) in challenge studies with severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) and mice expressing the human angiotensin-converting enzyme 2 receptor.
Intramuscular dosing of ChAd-SARS-CoV-2-S induces robust systemic humoral and cell-mediated immune
responses and protects against lung infection, inflammation, and pathology but does not confer sterilizing
immunity, as evidenced by detection of viral RNA and induction of anti-nucleoprotein antibodies after
SARS-CoV-2 challenge. In contrast, a single intranasal dose of ChAd-SARS-CoV-2-S induces high levels
of neutralizing antibodies, promotes systemic and mucosal immunoglobulin A (IgA) and T cell responses,
and almost entirely prevents SARS-CoV-2 infection in both the upper and lower respiratory tracts. Intranasal
administration of ChAd-SARS-CoV-2-S is a candidate for preventing SARS-CoV-2 infection and transmission
and curtailing pandemic spread.INTRODUCTION
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
is a positive-sense, single-stranded RNA virus that was first iso-
lated in late 2019 from patients with severe respiratory illness in
Wuhan, China (Zhou et al., 2020b). SARS-CoV-2 is related to two
other highly pathogenic respiratory viruses, SARS-CoV andMid-
dle East respiratory syndrome coronavirus (MERS-CoV). SARS-
CoV-2 infection results in a clinical syndrome, coronavirus dis-
ease 2019 (COVID-19), that can progress to respiratory failure
(Guan et al., 2020) and also present with cardiac pathology,
gastrointestinal disease, coagulopathy, and a hyperinflamma-tory syndrome (Cheung et al., 2020; Mao et al., 2020; Wichmann
et al., 2020). The elderly, immunocompromised, and those with
certain co-morbidities (e.g., obesity, diabetes, and hypertension)
are at greatest risk of death from COVID-19 (Zhou et al., 2020a).
Virtually all countries and territories have been affected with
more than twenty-seven million infections to date, hundreds of
thousands of deaths, and a case-fatality rate estimated at
4%. The extensive morbidity, mortality, and destabilizing so-
cioeconomic consequences of COVID-19 highlight the urgent
need for deployment of an effective SARS-CoV-2 vaccine to
mitigate the severity of infection, curb transmission, end the
pandemic, and prevent its return.Cell 183, 169–184, October 1, 2020 ª 2020 Elsevier Inc. 169
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length. The 50 two-thirds encode nonstructural proteins that
enable genome replication and viral RNA synthesis. The remain-
ing one-third encode structural proteins, such as spike (S), enve-
lope, membrane, and nucleoprotein (NP), that form the spherical
virion and accessory proteins that regulate cellular responses.
The S protein forms homotrimeric spikes on the virion and en-
gages the cell-surface receptor angiotensin-converting enzyme
2 (ACE2) to promote coronavirus entry into human cells (de Wit
et al., 2016; Letko et al., 2020). The SARS-CoV and SARS-
CoV-2 S proteins are cleaved sequentially during the entry pro-
cess to yield S1 and S2 fragments, followed by further process-
ing of S2 to yield a smaller S20 protein (Hoffmann et al., 2020).
The S1 protein includes the receptor binding domain (RBD),
and the S2 protein promotes membrane fusion. The structure
of a soluble, stabilized prefusion form of the SARS-CoV-2 S pro-
tein was solved by cryoelectron microscopy, revealing consider-
able similarity to the SARS-CoV S protein (Wrapp et al., 2020).
This form of the S protein is recognized by potently neutralizing
monoclonal antibodies (Cao et al., 2020; Pinto et al., 2020;
Zost et al., 2020) and could serve as a promising vaccine target.
Release of the SARS-CoV-2 genome sequence spurred im-
mediate development of vaccine candidates that principally tar-
geted the viral S protein (Burton andWalker, 2020). Multiple plat-
forms have been developed to deliver the SARS-CoV-2 S
protein, including DNA plasmid, lipid nanoparticle encapsulated
mRNA, inactivated virion, and viral-vectored vaccines (Graham,
2020). Several vaccines have entered clinical trials to evaluate
safety, and some have advanced to trials assessing immunoge-
nicity and efficacy. Most vaccines advanced to human testing
without substantive efficacy data in animals (Diamond and Pier-
son, 2020). This circumstance occurred in part because vaccine
design and development outpaced the generation of accessible
pre-clinical disease models of SARS-CoV-2 infection and
pathogenesis.
Adenovirus (Ad)-based vaccines against coronaviruses have
been evaluated previously. A single dose of a chimpanzee Ad-
vectored vaccine encoding the S protein of MERS-CoV pro-
tected mice from infection (Munster et al., 2017), reduced virus
shedding, and enhanced survival in camels (Alharbi et al.,
2019) and was safe and immunogenic in humans in a phase 1
clinical trial (Folegatti et al., 2020a). A human Ad-based vaccine
expressing a MERS S1-CD40L fusion protein also was protec-
tive in mice (Hashem et al., 2019). An Ad-based SARS-CoV vac-
cine expressing the S protein prevented pneumonia in ferrets af-
ter challenge and was highly immunogenic in rhesus macaques
(Kobinger et al., 2007). A chimpanzee Ad vector (Y25, a simian
Ad-23; Dicks et al., 2012) encoding the SARS-CoV-2 S protein
(ChAdOx1 nCoV-19) is currently under evaluation in humans as
a single intramuscular injection (NCT04324606). In rhesus ma-
caques, this vaccine protects against lung infection and pneu-
monia, but not against upper respiratory tract infection and virus
shedding (van Doremalen et al., 2020).
Here, we develop a different chimpanzee Ad (simian Ad-36)-
based SARS-CoV-2 vaccine (ChAd-SARS-CoV-2-S) encoding
a prefusion stabilized spike (S) protein after introducing two pro-
line substitutions in the S2 subunit (Pallesen et al., 2017). Intra-
muscular administration of ChAd-SARS-CoV-2-S induced170 Cell 183, 169–184, October 1, 2020robust systemic humoral and cell-mediated immune responses.
One or two vaccine doses protected against lung infection,
inflammation, and pathology after SARS-CoV-2 challenge of
mice that transiently express the human ACE2 (hACE2) receptor.
Despite the induction of high levels of neutralizing antibody,
neither dosing regimen completely protected against SARS-
CoV-2 infection, as substantial levels of viral RNA were still de-
tected in the lung. In comparison, a single intranasal dose of
ChAd-SARS-CoV-2-S induced high levels of neutralizing anti-
body and anti-SARS-CoV-2 immunoglobulin A (IgA) and
conferred virtually complete protection against infection in both
the upper and lower respiratory tracts in mice expressing
hACE2 receptor after adenoviral vector delivery or as a trans-
gene. Thus, intranasal immunization of ChAd-SARS-CoV-2-S
has the potential to control infection at the site of inoculation,
which should prevent both virus-induced disease and
transmission.RESULTS
Chimpanzee Ad-Vectored Vaccine Induces Robust
Antibody Responses against SARS-CoV-2
We constructed two replication-incompetent ChAd vectors
based on a simian Ad-36 virus. The ChAd-SARS-CoV-2-S vector
encodes the full-length, codon optimized sequence of SARS-
CoV-2 S protein as a transgene, including the ectodomain,
transmembrane domain, and cytoplasmic domain (GenBank:
QJQ84760.1), and is stabilized in prefusion form by two proline
substitutions at residues K986 and V987 (Pallesen et al., 2017;
Wrapp et al., 2020). The ChAd-control has no transgene. The S
protein transgene is controlled transcriptionally by a cytomega-
lovirus promoter. To make the vector replication incompetent
and enhance packaging capacity, we replaced the E1A/B genes
and introduced a deletion in the E3B gene, respectively (Fig-
ure 1A). To confirm that the S protein was expressed and anti-
genically intact, we transduced 293T cells and confirmed binding
of a panel of 22 neutralizing monoclonal antibodies against the S
protein by flow cytometry (Figure 1B).
To assess the immunogenicity of ChAd-SARS-CoV-2-S,
groups of 4-week-old BALB/c mice were immunized by intra-
muscular inoculation with 1010 virus particles of ChAd-SARS-
CoV-2-S or ChAd-control. Some mice received a booster dose
4 weeks later. Serum samples were collected 21 days after pri-
mary or booster immunization (Figure 1C), and IgG responses
against purified S and RBD proteins were evaluated by ELISA.
Whereas ChAd-SARS-CoV-2-S induced high levels of S- and
RBD-specific IgG, low if any levels were detected in the ChAd-
control-immunized mice (Figure 1D). However, intramuscular in-
jection of ChAd-SARS-CoV-2-S failed to induce S- or RBD-spe-
cific IgA in serum (Figure 1E). We next functionally characterized
serum antibody responses by assaying neutralization of infec-
tious SARS-CoV-2 using a focus-reduction neutralization test
(FRNT) (Case et al., 2020). As expected, serum from ChAd-con-
trol-immunized mice did not inhibit SARS-CoV-2 infection after
primary immunization or boosting. In contrast, serum from
ChAd-SARS-CoV-2-S-vaccinated animals neutralized SARS-
CoV-2 infection, and boosting enhanced this inhibitory activity
(legend on next page)
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Figures 1F, S1A, and S1B).
Vaccine-Induced Memory CD8+ T Cell and Antigen-
Specific B Cell Responses
Because optimal vaccine immunity is often composed of both
humoral and cellular responses (Slifka and Amanna, 2014), we
measured the levels of SARS-CoV-2-specific CD4+ and CD8+
T cells after vaccination. 4-week-old BALB/c mice were immu-
nized with ChAd-SARS-CoV-2-S or ChAd-control and boosted
3weeks later. To assess the vaccine-induced SARS-CoV-2-spe-
cific CD4+ and CD8+ T cell responses, splenocytes were har-
vested 1 week after boosting and stimulated ex vivo with a
pool of 253 overlapping 15-mer S peptides (Table S1). Subse-
quently, quantification of intracellular interferon g (IFNg) and
granzyme B expression was determined by flow cytometry. After
peptide re-stimulation ex vivo, splenic CD8+ T cells expressed
IFNg and both splenic CD4+ and CD8+ T cells expressed gran-
zyme B in mice immunized with ChAd-SARS-CoV-2-S, but not
the ChAd-control vector (Figures 1G, 1H, and S2). To assess
the antigen-specific B cell responses, splenocytes were har-
vested and subjected to an ELISPOT analysis with S protein.
The ChAd-SARS-CoV-2-S vaccine induced S-protein-specific
IgG antibody-secreting cells in the spleen, whereas the control
vaccine did not (Figure 1I).
To assess whether intramuscular vaccination could induce
mucosal immune responses in the lungs, mice were immunized
with either ChAd-SARS-CoV-2-S or ChAd-control and boosted
similarly 4 weeks later. Lungs were harvested 1 week post-
boosting, and T cells were analyzed by flow cytometry. Notably,
we failed to detect an increase in IFNg or granzyme B producing
CD8+ T cells in the lungs of ChAd-SARS-CoV-2-S vaccinated
mice after re-stimulation ex vivo with a pool of S peptides (Fig-
ure 1J) or CD103+CD69+CD8+ cells that could represent lung-
resident memory T cells (Figure 1K). In the spleen, we also failed
to detect antibody-secreting plasma cells producing IgA against
the S protein after immunization with ChAd-SARS-CoV-2-S (Fig-
ure 1L). Moreover, we detected lowS-specific IgG and noS-spe-
cific IgA or RBD-specific IgG or IgA antibodies in bronchoalveo-
lar lavage (BAL) fluid of immunized mice (Figures 1M and 1N).
Thus, although intramuscular vaccination with ChAd-SARS-Figure 1. Immunogenicity of ChAd-SARS-CoV-2-S
(A) Diagram of transgene cassettes: ChAd-control has no transgene insert; ChA
proline mutations.
(B) Binding of ChAd-SARS-CoV-2-S transduced 293 cells with anti-SmAbs. (Left)
respectively. MFI, mean fluorescence intensity. (Right) Representative flow cytom
(C–F) Four-week-old female BALB/c mice were immunized via intramuscular ro
Antibody responses in sera of immunizedmice at day 21 after priming or boosting
[E]), and an FRNT determined neutralization activity (F). Data are pooled from tw
(G and H) Cell-mediated responses were analyzed at day 7 post-booster immuniz
were assayed for IFNg and granzyme B expression in CD8+ T cells and granzym
numbers of positive cell populations is shown in (H) (n = 5). Bars indicate median
(I) Spleens were harvested at 7 days post-boost, and SARS-CoV-2 spike-specific Ig
(J) CD8+ T cells in the lung were assayed for IFNg and granzyme B expression b
(K) Lung CD8+ T cells also were assayed for expression of CD69 and CD103.
(L) Spleens were harvested at 7 days post-boosting, and SARS-CoV-2 spike-spe
(M and N) SARS-CoV-2 S- (M) and RBD-specific (N) IgG and IgA levels in BAL fl
Bars and columns show median values, and dotted lines indicate the limit of dete
0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001; ns, not significant. See Figures S1,
172 Cell 183, 169–184, October 1, 2020CoV-2-S produced strong systemic adaptive immune responses
against SARS-CoV-2, it induced minimal mucosal immune
response.
Intramuscular Immunization with ChAd-SARS-CoV-2-S
Vaccine Protects against SARS-CoV-2 Infection in
the Lung
We tested the protective activity of the ChAd vaccine in a
recently developed SARS-CoV-2 infection model, wherein
BALB/c mice express hACE2 in the lung after intranasal delivery
of a vectored human Ad (Hu-Ad5-hACE2; Hassan et al., 2020).
Endogenous mouse ACE2 does not support viral entry (Letko
et al., 2020), and this system enables productive SARS-CoV-2
infection in the mouse lung. 4-week-old BALB/c mice first were
immunized via an intramuscular route with ChAd-control or
ChAd-SARS-CoV-2-S vaccines. Approximately 30 days later,
mice were administered 108 plaque-forming units (PFUs) of
Hu-Ad5-hACE2 and anti-Ifnar1 monoclonal antibody (mAb) via
intranasal and intraperitoneal routes, respectively. We adminis-
tered a single dose of anti-Ifnar1mAb to enhance lung pathogen-
esis in this model (Hassan et al., 2020). We confirmed the
absence of cross-immunity between the ChAd and the Hu-Ad5
vector. Serum from ChAd-immunized mice did not neutralize
Hu-Ad5 infection (Figures S3A and S3B).
5 days after Hu-Ad5-hACE2 transduction, mice were chal-
lenged via intranasal route with 4 3 105 focus-forming units
(FFUs) of SARS-CoV-2 (Figure 2A). At 4 days post-infection
(dpi), the peak of viral burden in this model (Hassan et al.,
2020), mice were euthanized and lungs, spleen, and heart were
harvested for viral burden and cytokine analysis. Notably, there
was no detectable infectious virus in the lungs of mice immu-
nized with ChAd-SARS-CoV-2-S as determined by plaque
assay, whereas high levels were present in mice vaccinated
with ChAd-control (Figure 2B). Using primers that target a
sequence within the N gene, we also detected no measurable
genomic or subgenomic viral RNA in the heart and spleen and
lower levels of viral RNA in the lungs of ChAd-SARS-CoV-2-S-
vaccinated animals compared to mice receiving the ChAd-con-
trol vector (Figure 2C). In situ hybridization staining for viral RNA
in lungs harvested at 4 dpi revealed a substantial decrease of
SARS-CoV-2 RNA in pneumocytes of animals immunized withd-SARS-CoV-2-S encodes for SARS-CoV-2 S protein with the two indicated
Summary: +, ++, +++, and - indicate <25%, 25%–50%, >50%, and no binding,
etry histograms of two experiments are shown.
ute with ChAd-control or ChAd-SARS-CoV-2-S and boosted 4 weeks later.
were evaluated. An ELISAmeasured anti-S and RBD IgG and IgA levels ([D] and
o experiments (n = 15–30).
ation after re-stimulation with an S protein peptide pool (Table S1). Splenocytes
e B only in CD4+ T cells by flow cytometry (G). A summary of frequencies and
values, and dotted lines are the limit of detection (LOD) of the assays.
G+ antibody-secreting cell (ASC) frequency was measured by ELISPOT (n = 13).
y flow cytometry after re-stimulation with an S protein peptide pool (n = 4–5).
cific IgA+ ASC frequency was measured by ELISPOT (n = 4–5).
uid were determined by ELISA (n = 4–5).
ction (LOD) of the assays. For (D), (F), (H), (I), and (J): Mann-Whitney test: *p <
S2, and S3 and Table S1.
(legend on next page)
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Figure 3. Single-Dose Intramuscular Vaccination with ChAd-SARS-CoV-2-S Protects Mice against SARS-CoV-2-Induced Inflammation in
the Lung
Four-week-old female BALB/c mice were immunized with ChAd-control and ChAd-SARS-CoV-2-S and challenged following the scheme described in Figure 2.
Lungs were harvested at 8 dpi. Sections were stained with hematoxylin and eosin and imaged at 403 (left; scale bar, 250 mm), 2003 (middle; scale bar, 50 mm),
and 4003 (right; scale bar, 25 mm) magnifications. Each image is representative of a group of 3 mice.
ll
ArticleChAd-SARS-CoV-2-S compared to the ChAd-control (Fig-
ure 2D). A subset of immunized animals was euthanized at 8
dpi, and tissues were harvested for evaluation. At this time point,
viral RNA levels again were lower or absent in the lung and
spleen of ChAd-SARS-CoV-2-S-immunized mice compared to
the control ChAd vector (Figure 2C). Collectively, these data indi-
cate that a single intramuscular immunization with ChAd-SARS-
CoV-2-S results in markedly reduced, but not abrogated, SARS-
CoV-2 infection in the lungs of challenged mice.
Wenext assessed the effectof the vaccineon lung inflammation
and disease. Several proinflammatory cytokines and chemokine
mRNA levels were lower in the lung tissues of animals immunized
with ChAd-SARS-CoV-2-S compared to ChAd-control, including
interleukin (IL)-1b, CXCL10, IFNb, IFNl, IL-6, and CXCL11 (Fig-
ure 2E). Moreover, mice immunized with ChAd-control vaccineFigure 2. Protective Efficacy of Intramuscularly Delivered ChAd-SARS
(A) Scheme of vaccination and challenge. Four-week-old BALB/c female mice w
booster dose of the homologous vaccine. On day 35 post-immunization, micewer
mAb and transduced with Hu-AdV5-hACE2 via an intranasal route 1 day later. Fiv
SARS-CoV-2 via the intranasal route.
(B and C) Tissues were harvested at 4 and 8 dpi for analysis. Infectious virus in the
the lung, spleen, and heart at 4 and 8 dpi by qRT-PCR (C; n = 3–7).
(D) Viral RNA in situ hybridization using SARS-CoV-2 probe (brown color) in the lun
(middle; scale bars, 100 mm) power magnification with a high-power magnificatio
(E) Fold change in gene expression of indicated cytokines and chemokines from
Gapdh levels and comparison with naive unvaccinated, unchallenged controls (n
(F and G) Mice that received a prime-boost immunization were challenged on da
Infectious virus in the lung was determined by plaque assay (F), and viral RNA w
(B, C, and E–G) Columns show median values, and dotted lines indicate the LOD
0.01; ***p < 0.001. See Figure S3.
174 Cell 183, 169–184, October 1, 2020and challengedwith SARS-CoV-2 showed evidence of viral pneu-
monia characterized by immune cell accumulation in perivascular
and alveolar locations, vascular congestion, and interstitial
edema. In contrast, animals immunized with ChAd-SARS-CoV-
2-S showed a marked attenuation of the inflammatory response
in the lung that develops in the ChAd-control-immunized mice
(Figure 3). Thus, immunization with Ch-Ad-SARS-CoV-2 de-
creases both viral infection and the consequent lung inflammation
and injury associated with SARS-CoV-2 infection.
We thenassessed for improvedprotection usingaprime-boost
vaccine regimen. BALB/c mice were immunized via an intramus-
cular route with ChAd-control or ChAd-SARS-CoV-2-S and
received a homologous booster dose 4 weeks later. At day 29
post-boost, mice were treated with a single dose of anti-Ifnar1
antibody followed by Hu-Ad5-hACE2 and then challenged with-CoV-2-S against SARS-CoV-2 Infection
ere immunized ChAd-control or ChAd-SARS-CoV-2-S. Some mice received a
e challengedwith SARS-CoV-2 as follows: animals were treatedwith anti-Ifnar1
e days later, mice were challenged with 4 3 105 focus-forming units (FFUs) of
lung wasmeasured by plaque assay (B), and viral RNA levels were measured in
gs harvested at 4 dpi. Images show low- (top; scale bars, 100 mm) andmedium-
n inset (representative images from n = 3 per group).
lung homogenates at 4 dpi was determined by qRT-PCR after normalization to
= 7).
y 35 post-booster immunization. Tissues were collected at 4 dpi for analysis.
as measured in the lung, spleen, and heart using qRT-PCR (G; n = 6–7).
of the assays. For (B), (C), (E), (F), and (G): Mann-Whitney test: *p < 0.05; **p <
Figure 4. Immune Responses after Intranasal Immunization of ChAd-SARS-CoV-2-S
(A) Scheme of experiments. 5-week-old BALB/c female mice were immunized with ChAd-control or ChAd-SARS-CoV-2-S via an intranasal route.
(B–D) Antibody responses in sera of immunized mice at 1month after priming were evaluated. An ELISAmeasured SARS-CoV-2 S- and RBD-specific IgG (B) and
IgA levels (C), and a FRNT determined neutralization activity (D). Data are pooled from two experiments with n = 10–25 mice per group.
(E–J) Mice that received a booster dose were sacrificed 1 week later to evaluate mucosal and cell-mediated immune responses. SARS-CoV-2 S- and RBD-
specific IgG (E) and IgA levels (F) in BAL fluid were determined by ELISA. Neutralizing activity of BAL fluid against SARS-CoV-2 wasmeasured by FRNT (G). CD8+
T cells in the lung were assayed for IFNg and granzyme B expression by flow cytometry after re-stimulation with an S protein peptide pool (H). CD8+ T cells in the
(legend continued on next page)
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ArticleSARS-CoV-2 5 days later. As expected, the prime-boost regimen
protected against SARS-CoV-2 challengewith no infectious virus
detected in the lungs (Figure 2F). Although marked reductions of
viral RNA in the lung, spleen, and heart were detected at 4 dpi, re-
sidual levels of viral RNA still were present, suggesting protection
was not complete, even after boosting (Figure 2G).A Single Intranasal Immunization with ChAd-SARS-CoV-
2-S Induces Protective Immunity against SARS-CoV-2 in
Mice Expressing hACE2 Delivered by an Adenoviral
Vector
Mucosal immunization through the nasopharyngeal route can
elicit local immune responses, including secretory IgA antibodies
that confer protection at or near the site of inoculation of respira-
tory pathogens (Neutra and Kozlowski, 2006). To assess the
immunogenicity and protective efficacy of mucosal vaccination,
5-week-old BALB/c mice were inoculated via intranasal route
with 1010 viral particles of ChAd-control or ChAd-SARS-CoV-
2-S (Figure 4A). Serum samples were collected at 4 weeks
post-immunization to evaluate humoral immune responses.
Intranasal immunization of ChAd-SARS-CoV-2-S, but not
ChAd-control, induced high levels of S- and RBD-specific IgG
and IgA (Figures 4B and 4C) and SARS-CoV-2-neutralizing anti-
bodies (GMT of 1/1,574) in serum (Figures 4D and S4A). Anti-
bodies from mice immunized with ChAd-SARS-CoV-2-S equiv-
alently neutralized a recombinant, luciferase-expressing variant
of SARS-CoV-2 encoding aD614Gmutation in the S protein (Fig-
ure S4B); this finding is important, because many circulating vi-
ruses contain this substitution, which is associated with greater
infectivity in cell culture (Korber et al., 2020). We also assessed
the SARS-CoV-2-specific antibody responses in BAL fluid of
immunized mice. BAL fluid from ChAd-SARS-CoV-2-S-, but
not ChAd-control-, vaccinated mice showed high levels of S-
and RBD-specific IgG and IgA antibodies (Figures 4E and 4F),
including those with neutralizing activity (Figures 4G and S4C).
To assess T cell responses activated via mucosal immuniza-
tion, mice were vaccinated via intranasal route with either
ChAd-SARS-CoV-2-S or ChAd-control and boosted similarly
4 weeks later. Lungs were harvested 1 week post-boosting,
and T cells were analyzed by flow cytometry. Re-stimulation
ex vivo with a pool of S peptides resulted in a marked increase
in IFNg and granzyme B producing CD8+ T cells in the lungs of
mice that received the ChAd-SARS-CoV-2-S vaccine (Fig-
ure 4H). Specifically, a population of IFNg-secreting, antigen-
specific CD103+CD69+CD8+ T cells in the lung was identified
(Figure 4I), which is phenotypically consistent with vaccine-
induced resident memory T cells (Takamura, 2017). In the
spleen, we detected antibody-secreting plasma cells producing
IgA or IgG against the S protein after intranasal immunization
with ChAd-SARS-CoV-2-S (Figure 4J). Of note, we observed
an 5-fold higher frequency of B cells secreting anti-S IgA
than IgG.lung also were phenotyped for expression of CD103 and CD69 (I). SARS-CoV-2 sp
boost wasmeasured by ELISPOT (J). Data for mucosal and cell-mediated respons
(B–J) Bars and columns show median values, and dotted lines indicate the LOD
Figure S4 and Table S1.
176 Cell 183, 169–184, October 1, 2020We evaluated the protective efficacy of the ChAd vaccine after
single-dose intranasal immunization. At day 30 post-vaccina-
tion, mice were administered 108 PFUs of Hu-Ad5-hACE2 and
anti-Ifnar1 mAb as described above. 5 days later, mice were
challenged with 4 3 105 FFUs of SARS-CoV-2. At 4 and 8 dpi,
lungs, spleen, heart, nasal turbinates, and nasal washes were
harvested and assessed for viral burden. Intranasal delivery of
the ChAd-SARS-CoV-2-S vaccine demonstrated remarkable
protective efficacy as judged by an absence of infectious virus
in the lungs (Figure 5A) and almost no measurable viral RNA in
the lung, spleen, heart, nasal turbinates, or nasal washes, as
determined with subgenomic/genomic (N gene) or genomic
only (ORF1a gene) TaqMan probes (Figures 5B and S4D). The
very low viral RNA levels in the lung and nasal turbinates at 4
dpi may reflect the input, non-replicating virus, as similar
amounts were measured at this time point in C57BL/6 mice lack-
ing hACE2 receptor expression (Hassan et al., 2020). Cytokine
and chemokine mRNA levels in lung homogenates also were
substantially lower in mice immunized with the ChAd-SARS-
CoV-2-S than the ChAd-control vaccine (Figure 5C), with resid-
ual expression likely due to the human Ad vector hACE2 delivery
system. Finally, histopathological analysis of lung tissues from
animals vaccinated with ChAd-SARS-CoV-2-S by intranasal
route and challenged with SARS-CoV-2 showed minimal, if
any, perivascular and alveolar infiltrates at 8 dpi compared to
the extensive inflammation observed in ChAd-control-vacci-
nated animals (Figure 5D).
To begin to determine whether sterilizing immunity might be
achieved with intranasal delivery of ChAd-SARS-CoV-2-S, we
measured anti-NP antibodies at 8 dpi and compared them to
responses from 5 days before SARS-CoV-2 infection. Because
the NP gene is absent from the vaccine vector, induction of hu-
moral immune responses against NP after SARS-CoV-2 expo-
sure (Ni et al., 2020) suggests viral protein translation and
active infection. After SARS-CoV-2 challenge, anti-NP antibody
responses were detected in ChAd-control mice vaccinated by
an intranasal route or ChAd-control and ChAd-SARS-CoV-2-S
mice vaccinated by an intramuscular route (Figures 5E and
S1C). Remarkably, none of the mice immunized with ChAd-
SARS-CoV-2-S via an intranasal route showed significant in-
creases in anti-NP antibody responses after SARS-CoV-2
infection (Figures 5E and S5). Combined with our virological an-
alyses, these data suggest that a single intranasal immunization
of ChAd-SARS-CoV-2-S induces robust mucosal immunity,
which prevents SARS-CoV-2 infection in the upper and lower
respiratory tracts of mice expressing the hACE2 receptor.A Single Intranasal Immunization with ChAd-SARS-CoV-
2-S Prevents SARS-CoV-2 Infection in the Upper and
Lower Respiratory Tracts of hACE2 Transgenic Mice
Recently, we and others established a more stringent, lethal
SARS-CoV-2 challenge model (Rathnasinghe et al., 2020;ike-specific IgG+ and IgA+ ASC frequency in the spleen harvested 1week post-
es are pooled from two experiments (E–I: n = 7–9 per group; J: n = 5 per group).
of the assays. Mann-Whitney test: **p < 0.01; ***p < 0.001; ****p < 0.0001. See
Figure 5. Single-Dose Intranasal Immunization with ChAd-SARS-CoV-2-S Protects against SARS-CoV-2 Infection
Five-week-old BALB/c femalemicewere immunized with ChAd-control or ChAd-SARS-CoV-2-S via an intranasal route. On day 35 post-immunization,micewere
challenged as follows: animals were treated with anti-Ifnar1 mAb and transduced with Hu-AdV5-hACE2 via the intranasal route 1 day later. Five days later, mice
were challenged intranasally with 4 3 105 FFUs of SARS-CoV-2.
(legend continued on next page)
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eight inserted copies of the hACE2 gene driven by the K18 cy-
tokeratin epithelial cell promoter (McCray et al., 2007). Within
1 week of SARS-CoV-2 inoculation by an intranasal route,
K18-hACE2 mice develop severe lung infection and inflamma-
tion, immune cell infiltration, and compromised respiratory
function that results in death. As an independent test of the ef-
ficacy of intranasal administration of ChAd-SARS-CoV-2-S,
we assessed its immunogenicity and protective efficacy in
K18-hACE2 mice.
4-week-old K18-hACE2micewere inoculated via an intranasal
route with 1010 viral particles of ChAd-control or ChAd-SARS-
CoV-2-S (Figure 6A). Serum samples were collected at 4 weeks
post-immunization, and humoral immune responses were evalu-
ated. Intranasal immunization of ChAd-SARS-CoV-2-S, but not
ChAd-control, induced high levels of S- and RBD-specific IgG
and IgA (Figures 6B and 6C) and neutralizing antibodies (GMT
of 1/1,424) in serum (Figures 6D and S6). At day 30 post-vacci-
nation, K18-hACE2 mice were challenged via an intranasal route
with 103 FFUs of SARS-CoV-2. At 4 dpi, lungs, spleen, heart,
nasal turbinates, and nasal washes were harvested and as-
sessed for viral burden. Similar to that seen in BALB/c mice tran-
siently expressing hACE2, intranasal immunization of ChAd-
SARS-CoV-2-S conferred remarkable protection as judged by
an absence of infectious virus in the lungs (Figure 6E), no
measurable viral subgenomic/genomic RNA in the lungs or
hearts, and very low levels of viral RNA in the nasal turbinates
or washes (Figure 6F). Consistent with these results, after
SARS-CoV-2 challenge, we observed no induction of cytokine
and chemokine mRNA (e.g., CCL2, CXCL1, CXCL10, CXCL11,
IL-6, IFNb, and IFNl) in the lung homogenates of ChAd-SARS-
CoV-2-S-immunized compared to naive mice, whereas ChAd-
control-vaccinated mice sustained high levels (Figure 6G).
Collectively, these data suggest that a single intranasal immuni-
zation of ChAd-SARS-CoV-2-S induces robust systemic and
mucosal immunity that blocks SARS-CoV-2 infection in the
upper and lower respiratory tract of highly susceptible K18-
hACE2 transgenic mice.
DISCUSSION
In this study, we evaluated intramuscular and intranasal admin-
istration of a replication-incompetent ChAd vector as a vaccine
platform for SARS-CoV-2. Single-dose immunization of a stabi-
lized S-protein-based vaccine via an intramuscular route
induced S- and RBD-specific binding as well as neutralizing
antibodies. Vaccination with one or two doses protected mice
expressing human ACE2 against SARS-CoV-2 challenge, as(A–C) Tissues and nasal washes were collected at 4 and 8 dpi for analysis. Infecti
lung, spleen, heart, nasal turbinates, and nasal washes weremeasured at 4 and 8 d
chemokines was determined by qRT-PCR, normalized to Gapdh, and compare
median values are shown). Columns show median values, and dotted lines indic
(D) Lungs were harvested at 8 dpi. Sections were stainedwith hematoxylin and eos
and 4003 (right; scale bar, 25 mm) magnifications. Each image is representative
(E) An ELISA measured anti-SARS-CoV-2 NP IgM (left) and IgG (right) antibody re
challenge of ChAd-control or ChAd-SARS-CoV-2-S mice vaccinated by an intra
indicate the mark for a 4-fold increase of pre-boost IgM and IgG levels.
For (A)–(C): Mann-Whitney test: *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001
178 Cell 183, 169–184, October 1, 2020evidenced by an absence of infectious virus in the lungs and sub-
stantially reduced viral RNA levels in lungs and other organs.
Mice immunized with ChAd-SARS-CoV-2-S also showed mark-
edly reduced if not absent lung pathology, lung inflammation,
and evidence of pneumonia compared to the control ChAd vac-
cine. However, intramuscular vaccination of ChAd-SARS-CoV-
2-S did not induce IgA responses or confer sterilizing immunity,
as evidenced by detectable viral RNA levels in the lung and in-
duction of anti-NP antibody responses. Mice immunized with a
single dose of the ChAd-SARS-CoV-2-S via an intranasal route
also were protected against SARS-CoV-2 challenge. Intranasal
vaccination, however, generated robust IgA and neutralizing
antibody responses that likely protected against both upper
and lower respiratory tract SARS-CoV-2 infection and inhibited
infection of both wild-type and D614G variant viruses. The very
low levels of genomic viral RNA in upper airway tissues and
absence of serological response to NP in the context of chal-
lenge strongly suggests that at least some animals receiving a
single intranasal dose of ChAd-SARS-CoV-2-S likely achieved
sterilizing immunity.
Although several vaccine candidates (e.g., lipid-encapsulated
mRNA, DNA, inactivated, and viral vectored) rapidly advanced to
human clinical trials in an expedited effort to control the
pandemic (Amanat and Krammer, 2020), few studies have
demonstrated efficacy in pre-clinical models. Rhesus macaques
immunizedwith two or three doses of a DNA plasmid vaccine en-
coding full-length SARS-CoV-2 S protein induced neutralizing
antibody in sera and reduced viral burden in BAL and nasal mu-
cosa fluids (Yu et al., 2020). Three immunizations over 2 weeks
with purified, inactivated SARS-CoV-2 induced neutralizing anti-
bodies and, depending on the dose administered, provided par-
tial or complete protection against infection and viral pneumonia
in rhesus macaques (Gao et al., 2020). Finally, two intramuscular
doses of a lipid-encapsulated, mRNA-based vaccine against S
protected against SARS-CoV-2 infection in nasal swabs and
BAL fluid of rhesus macaques (Corbett et al., 2020). One limita-
tion of these challenge models is that rhesus macaques develop
lower viral burden and mild interstitial pneumonia after SARS-
CoV-2 infection compared to some humans and other non-hu-
man primate species (Chandrashekar et al., 2020; Munster
et al., 2020). Our study in hACE2-expressing mice shows that
a single intramuscular or intranasal dose of ChAd-SARS-CoV-
2-S vaccine confers substantial and possibly complete protec-
tion against viral replication, inflammation, and lung disease.
Our approach supports the use of non-human Ad-vectored
vaccines against emerging RNA viruses, including SARS-
CoV-2. Previously, we showed the efficacy of single-dose or
two-dose regimens of a gorilla Ad encoding the prM-E genesous virus in the lung was measured by plaque assay (A). Viral RNA levels in the
pi by qRT-PCR (B). Fold change in gene expression of indicated cytokines and
d to naive controls in lung homogenates at 4 dpi (C; 2 experiments, n = 6–9;
ate the LOD of the assays.
in and imaged at 403 (left; scale bar, 250 mm), 2003 (middle; scale bar, 50 mm),
of a group of 3 mice.
sponses in paired sera obtained 5 days before and 8 days after SARS-CoV-2
nasal route (n = 6). Dotted lines represent the LOD of the assay. Dashed lines
; for (E): **p < 0.01, ****p < 0.0001; paired t test. See Figures S4 and S5.
(legend on next page)
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Articleof Zika virus (ZIKV) in several mouse challenge models, including
in the context of pregnancy (Hassan et al., 2019). Others have
evaluated ChAd or rhesus macaque Ad vaccine candidates
against ZIKV and shown efficacy in mice and non-human pri-
mates (Abbink et al., 2016; López-Camacho et al., 2018). A
different ChAd encoding the wild-type SARS-CoV-2 S protein
(ChAdOx1) is currently in clinical trials in humans
(NCT04324606) and a phase 1/2 trial showed neutralizing anti-
body responses against SARS-CoV-2 in 91% and 100% partic-
ipants after one- or two-dose immunization regimens (Folegatti
et al., 2020b). Studies in rhesus macaques with ChAdOx1 sug-
gest that a single intramuscular dose protects against infection
in the lung, but not in the upper respiratory tract (van Doremalen
et al., 2020). None of the vaccines evaluated against SARS-CoV-
2 has shown evidence of immune enhancement in any pre-clin-
ical or clinical study, which has been a theoretical risk based on
studies with other human and animal coronaviruses (de Alwis
et al., 2020; Diamond and Pierson, 2020). Indeed, and in contrast
to data with SARS-CoV vaccines or antibodies (Bolles et al.,
2011; Liu et al., 2019; Weingartl et al., 2004), we did not observe
enhanced infection, immunopathology, or disease in animals
immunized with ChAd encoding SARS-CoV-2 S proteins or
administered passively transferred monoclonal antibodies (Al-
soussi et al., 2020; Hassan et al., 2020).
ChAd-SARS-CoV-2-S induced SARS-CoV-2-specific CD8+
T cell responses, including a high percentage and number of
IFNg- and granzyme-expressing cells after ex vivo Sprotein pep-
tide re-stimulation. The induction of CD8+ T cell responses by the
ChAd-SARS-CoV-2-S vaccine is consistent with reports with
other simian Ad vectors (Douglas et al., 2010; Hodgson et al.,
2015; Reyes-Sandoval et al., 2010). ChAd vaccine vectors not
only overcome issues of pre-existing immunity against human
adenoviruses but also have immunological advantages because
they do not induce exhausted T cell responses (Penaloza-Mac-
Master et al., 2013).
A single intranasal dose of ChAd-SARS-CoV-2-S conferred su-
perior immunity against SARS-CoV-2 challenge, more so than
one or two intramuscular immunizations of the same vaccine
and dose (Figure 7). Additionally, one intranasal dose of ChAd-
SARS-CoV-2-S prevented upper and lower respiratory tract
infection and inflammation by SARS-CoV-2 in highly susceptible
K18-hACE2 transgenic mice (Rathnasinghe et al., 2020; Winkler
et al., 2020). Given that the serum-neutralizing antibody re-
sponses were relatively comparable, we hypothesize the greater
protection observed after intranasal delivery was because of the
mucosal immune responses generated. Indeed, high levels of
anti-SARS-CoV-2 IgA were detected in serum and lung, and B
cells secreting IgA were detected in the spleen only inmice vacci-Figure 6. Immunogenicity and Protective Efficacy after Intranasal Imm
(A) Scheme of experiments. Four-week-old K18-hACE2 female mice were immu
(B–D) Antibody responses in sera of immunized mice at 4 weeks after priming wer
IgA levels (C), and a FRNT determined neutralization activity (D; n = 7).
(E–G) At 1 month post-immunization, mice were challenged with 103 FFUs of SAR
lungs was measured using plaque assay (E). Viral RNA levels in the lung, spleen, h
(F). Fold change in gene expression of indicated cytokines and chemokines was d
in lung homogenates at 4 dpi (G; n = 7). Boxes indicate median values, and dott
For (B)–(G): Mann-Whitney test: **p < 0.01; ***p < 0.001. See Figure S6.
180 Cell 183, 169–184, October 1, 2020nated via an intranasal route. Moreover, intranasal, but not intra-
muscular, vaccination induced SARS-CoV-2-specific CD8+
T cells in the lung, including CD103+CD69+ cells, which are likely
of a residentmemory phenotype. Future antibodypassive transfer
and T cell depletion studies can assess the relative contribution of
each immune arm to protection and establish more precisely the
mechanistic basis for the enhanced protection conferred by intra-
nasal delivery of ChAd-SARS-CoV-2-S.
To our knowledge, none of the SARS-CoV-2 vaccine platforms
currently in clinical trials use an intranasal delivery approach.
There has been great interest in using intranasal delivery for influ-
enza A virus vaccines because of their ability to elicit local hu-
moral and cellular immune responses (Calzas and Chevalier,
2019). Indeed, sterilizing immunity to influenza A virus re-infec-
tion requires local adaptive immune responses in the lung, which
is optimally induced by intranasal and not intramuscular inocula-
tion (Dutta et al., 2016; Laurie et al., 2010). Although there are
concerns with administering live-attenuated viral vaccines via
an intranasal route, subunit-based or replication-incompetent
vectored vaccines are promising for generating mucosal immu-
nity in a safer manner, especially given advances in formulation
(Yusuf and Kett, 2017).
Limitations of Study
Although a single intranasal administration of ChAd-SARS-
CoV-2-S protected against SARS-CoV-2 replication in lungs,
we note some limitations in our study. We performed most
challenge studies in mice transduced with hACE2 using a hu-
man Ad5 vector, which could be complicated by vector immu-
nity. Notwithstanding this possibility, we confirmed an absence
of heterologous neutralizing serum antibody induced by one or
two doses of ChAd vector against the Hu-Ad5 and, more
importantly, detected high levels of SARS-CoV-2 infection in
the ChAd-control-vaccinated mice after challenge. Moreover,
we reproduced the level of protection by ChAd-SARS-CoV-2-
S in K18-hACE2 transgenic mice. Immunization and challenge
studies with hamsters and non-human primates are planned
to confirm the extent of protective mucosal immunity conferred
by ChAd-SARS-CoV-2-S in mice and expand upon our under-
standing of how the route of inoculation impacts vaccine-medi-
ated protection. Moreover, studies in humans are needed to
assess for cross-immunity between the ChAd vector (simian
Ad-36) and adenoviruses circulating in humans. Although we
expect this will be much less than that observed with Hu-Ad5
vaccine vectors (Zhu et al., 2020), low levels of pre-existing im-
munity against simian adenoviruses could affect vaccine effi-
cacy in selected populations with non-human primate expo-
sures (e.g., zoo workers, veterinarians, and laboratoryunization of ChAd-SARS-CoV-2-S in K18-hACE2 Mice
nized with ChAd-control or ChAd-SARS-CoV-2-S via an intranasal route.
e evaluated. An ELISA measured SARS-CoV-2 S-and RBD-specific IgG (B) and
S-CoV-2. Tissues and nasal washes were harvested at 4 dpi. Infectious virus in
eart, nasal turbinates, and nasal washes were measured at 4 dpi by qRT-PCR
etermined by qRT-PCR, normalized toGapdh, and compared to naive controls
ed lines indicate the LOD of the assays.
Figure 7. Comparison of Immunogenicity of Single-Dose Administration of ChAd-SARS-CoV-2-S by Intramuscular and Intranasal Delivery
Routes
(Upper panel) After intramuscular inoculation, ChAd-SARS-CoV-2 vaccine transduces antigen-presenting cells (APCs) at the site of injection in muscle tissues.
APCsmigrate to lymphoid tissues where antigen-specific CD8+T cells become activated, proliferate, and produce IFNg and granzyme B. Antigen-specific B cells
proliferate, some of which become plasmablasts and plasma cells that secrete anti-S IgG. After SARS-CoV-2 challenge, activated CD8+ T cells migrate to the
lungs to control infection and anti-S IgG neutralizes virus particles. Intramuscular vaccination protects against lower, but not upper, airway infection and does not
efficiently induce mucosal immunity. (Lower panel) After intranasal inoculation, ChAd-SARS-CoV-2 transduces APCs in the upper respiratory tract. APCs then
migrate to bronchial- or mucosal-associated lymphoid tissues to present antigens to lymphocytes, including B and T cells. After SARS-CoV-2 challenge,
activated CD8+ T cells migrate to the lungs, secrete cytokines, and attack virus-infected cells. Some CD8+ T cells likely adopt a tissue-resident memory
phenotype (CD103+ CD69+), enabling them to reside in the lung (or upper airway) and respond more rapidly after re-encountering cognate antigen (SARS-
CoV-2 S peptides). The activated B cell becomes responsive after intranasal vaccination produces cells that secrete anti-SARS-CoV-2-S IgG or IgA, the latter of
which neutralizes virus within the upper and lower respiratory tracts. The mucosal immunity generated by intranasal inoculation of ChAd-SARS-CoV-2 likely
controls infection at the point of initiation in the upper respiratory tract.
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to monitor immune responses over time after intranasal vacci-
nation with ChAd-SARS-CoV-2-S to establish the durability of
the protective response.
In summary, our studies establish that immunization with
ChAd-SARS-CoV-2-S induces both neutralizing antibody and
antigen-specific CD8+ T cell responses. Although a single intra-
muscular immunization of ChAd-SARS-CoV-2-S confers pro-
tection against SARS-CoV-2 infection and inflammation in the
lungs, intranasal delivery of ChAd-SARS-CoV-2-S induces
mucosal immunity, provides superior protection, and possibly
promotes sterilizing immunity, at least in mice that transiently
or stably express the hACE2 receptor. We suggest that intra-
nasal delivery of ChAd-SARS-CoV-2-S is a promising platform
for preventing SARS-CoV-2 infection, disease, and upper
airway transmission and thus warrants clinical evaluation in
humans.
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Viruses and cells
Vero E6 (CRL-1586, American Type Culture Collection (ATCC), Vero CCL81 (ATCC), and HEK293 cells were cultured at 37C in Dul-
becco’s Modified Eagle medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 10 mM HEPES pH 7.3, 1 mM sodium
pyruvate, 1X non-essential amino acids, and 100 U/ml of penicillin–streptomycin
SARS-CoV-2 strain 2019 n-CoV/USA_WA1/2020 was obtained from the Centers for Disease Control and Prevention (a gift from
Natalie Thornburg). The virus was passaged once in Vero CCL81 cells and titrated by focus-forming assay (FFA) on Vero E6 cells.
The recombinant luciferase-expressing full-length SARS-CoV-2 reporter virus (2019 n-CoV/USA_WA1/2020 strain) has been re-
ported previously (Zost et al., 2020), and the D614G variant will be described elsewhere (R. Baric, manuscript in preparation). All
work with infectious SARS-CoV-2 was performed in Institutional Biosafety Committee approved BSL3 and A-BSL3 facilities using
appropriate positive pressure air respirators and protective equipment.
Mouse experiments
Animal studies were carried out in accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of
the National Institutes of Health. The protocols were approved by the Institutional Animal Care andUse Committee at theWashington
University School of Medicine (Assurance number A3381-01). Virus inoculations were performed under anesthesia that was induced
and maintained with ketamine hydrochloride and xylazine, and all efforts were made to minimize animal suffering.
Female BALB/c (catalog 000651) and K18-hACE2 C57BL/6 (catalog 034860) mice were purchased from The Jackson Laboratory.
Four to five-week-old animals were immunizedwith 1010 viral particles (vp) of ChAdV-empty or ChAd-SARS-CoV-2-S in 50 ml PBS via
intramuscular injection in the hind leg or via intranasal inoculation. Subsets of immunized animals were boosted four weeks after pri-
mary immunization using the same route used for primary immunization. Vaccinated BALB/c mice (10 to 11-week-old) were given a
single intraperitoneal injection of 2mg of anti-Ifnar1 mAb (MAR1-5A3 (Sheehan et al., 2006), Leinco) one day before intranasal admin-
istration of 108 PFUof Hu-AdV5-hACE2. Five days after Hu-AdV5 transduction,micewere inoculated with 43 105 FFU of SARS-CoV-
2 by the intranasal route. K18-hACE2 mice were challenged on day 30 after immunization with 103 PFU of SARS-CoV-2 via an intra-
nasal route. Animals were euthanized at 4 or 8 dpi, and tissues were harvested for virological, immunological, and pathological
analyses.
METHOD DETAILS
Construction of chimpanzee adenovirus vectors
Simian Ad36 vector (ChAd) (Roy et al., 2011) was obtained from the Penn Vector Core of the University of Pennsylvania. The ChAd
genome was engineered with deletions in the E1 and E3B region (GenBank: FJ025917.1; nucleotides 455-3026 and 30072-31869,Cell 183, 169–184.e1–e6, October 1, 2020 e3
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gene in reverse orientation on the complementary DNA strand. CMV modification included an addition of two copies of the tet oper-
ator 2 (TetO2) sequence (Hillen and Berens, 1994) inserted in tandem (50-TCT CTA TCA CTG ATA GGG AGA TCT CTA TCA CTG ATA
GG GA-30) between the TATA box and the mRNA start (GenBank: MN920393, nucleotides 174211-174212). SARS-CoV-2 S (Gen-
Bank MN908947.3; and two proline substitutions at residues K986 and V987 that stabilize the prefusion form of S (Pallesen et al.,
2017; Wrapp et al., 2020)) were cloned into a unique PmeI site under the CMV-tetO2 promoter control in pSAd36 genomic plasmid
to generate pSAd36-S. In parallel, a pSAd36-control carrying an empty CMV-tetO2 cassette with no transgene also was generated.
The pSAd36-S and pSAd-control plasmids were linearized with PacI restriction enzyme to liberate viral genomes for transfection into
T-Rex 293-HEK cells (Invitrogen). The rescued replication-incompetent ChAd-SARS-CoV-2-S and ChAd-Control vectors were
scaled up in 293 cells and purified byCsCl density-gradient ultracentrifugation. Viral particle concentration in each vector preparation
was determined by spectrophotometry at 260 nm as described (Maizel et al., 1968).
Construction of a human adenovirus vector expressing human ACE2
Codon-optimized hACE2 sequences were cloned into the shuttle vector (pShuttle-CMV, Addgene 240007) to generate pShuttle-
hACE2. pShuttle-hACE2 was linearized with PmeI and subsequently cotransformed with the HuAdv5 backbone plasmid (pA-
dEasy-1 vector; Addgene 240005) into E. coli strain BJ5183 to generate pAdV5-ACE2 by homologous recombination as described
(He et al., 1998). The pAdEasy-1 plasmid containing the HuAdV5 genome has deletions in E1 and E3 genes. hACE2 is under tran-
scriptional control of a cytomegalovirus promotor and is flanked at its 30 end by a SV40 polyadenylation signal. The pAd-hACE2
was linearized with PacI restriction enzyme before transfection into T-Rex 293 HEK cells (Invitrogen) to generate HuAdv5-hACE2.
Recombinant HuAdv5-hACE2was produced in 293-HEK cells and purified byCsCl density-gradient ultracentrifugation. The viral titer
was determined by plaque assay in 293-HEK cells.
In situ RNA hybridization and histology
RNA in situ hybridization was performed using RNAscope 2.5 HD (Brown) (Advanced Cell Diagnostics) according to the manufac-
turer’s instructions. Left lung tissues were collected at necropsy, inflated with 10% neutral buffered formalin (NBF), and thereafter
immersion fixed in 10% NBF for seven days before processing. Paraffin-embedded lung sections were deparaffinized by incubating
at 60C for 1 h, and endogenous peroxidases were quenchedwith H2O2 for 10min at room temperature. Slides were boiled for 15min
in RNAscope Target Retrieval Reagents and incubated for 30 min in RNAscope Protease Plus reagent prior to SARS-CoV2 RNA
probe (Advanced Cell Diagnostics 848561) hybridization and signal amplification. Sections were counterstained with Gill’s hematox-
ylin and visualized by brightfield microscopy. Some lung sections were processed for histology after hematoxylin and eosin staining.
SARS-CoV-2 neutralization assays
Heat-inactivated serum samples were diluted serially and incubated with 102 FFU of SARS-CoV-2 for 1 h at 37C. The virus-serum
mixtures were added to Vero cell monolayers in 96-well plates and incubated for 1 h at 37C. Subsequently, cells were overlaid with
1% (w/v) methylcellulose inMEMsupplementedwith 2%FBS. Plates were incubated for 30 h before fixation using 4%PFA in PBS for
1 h at room temperature. Cells were washed and then sequentially incubated with anti-SARS-CoV-2 CR3022 antibody (Yuan et al.,
2020) (1 mg/mL) and a HRP-conjugated goat anti-human IgG (Sigma) in PBS supplemented with 0.1% (w/v) saponin (Sigma) and
0.1% BSA. TrueBlue peroxidase substrate (KPL) was used to develop the plates before counting the foci on a BioSpot analyzer
(Cellular Technology Limited). For neutralization experiments with luciferase expressing SARS-CoV-2, serum samples were diluted
3-fold starting at 1:50 and mixed with 85 PFU of each recombinant virus (wild-type and D614G). Vero E6 cells plated in clear-bottom
black-walled 96-well plates (Corning) were inoculated with serum-virus mixtures, and cells were cultured at 37C for 48 h. Subse-
quently, cells were lysed and luciferase activity was measured using the Nano-Glo Luciferase Assay System (Promega) according
to the manufacturer’s specifications.
Hu-AdV5 neutralization assays
One day prior to Hu-AdV5-hACE2 transduction, serum samples were collected from mice immunized intramuscularly with ChAd-
Control or ChAd-SARS-CoV-2-S. Sera were heat-inactivated and serially diluted prior to incubation with 102 FFU of Hu-AdV5 for
1 h at 37C. The virus-serum mixtures were added to HEK293 cell monolayers in 96-well plates and incubated for 1 h at 37C. Cells
were then overlaid with 1% (w/v) methylcellulose in MEM supplemented with 5% FBS. Plates were incubated at 37C for 48 h before
fixationwith 2%PFA in PBS for 1 h at room temperature. Subsequently, plates werewashedwith PBS and incubated overnight at 4C
with biotinylated anti-HuAdV5-hexon antibody (2 mg/mL; Novus Biologicals NB600413) diluted in permeabilization buffer (PBS sup-
plemented with 0.1% (w/v) saponin and 0.1%BSA). Plates were washed again and incubated with streptavidin-HRP (1:3000; Vector
Laboratories SA-5004) in permeabilization buffer for 30 min at room temperature. After a final wash series, plates were developed
using TrueBlue peroxidase substrate (KPL) and foci were counted on a BioSpot analyzer (Cellular Technology Limited).
Protein expression and purification
Purified RNA from the 2019-nCoV/USA-WA1/2020 SARS-CoV-2 strain was reverse transcribed into cDNA and used as the
template for recombinant gene cloning. A full-length SARS-CoV-2 NP was cloned into pET21a with a hexahistidine tag ande4 Cell 183, 169–184.e1–e6, October 1, 2020
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1-thiogalactopyranoside (Goldbio) at 25C, cells were lysed in 20 mM Tris-HCl pH 8.5, 1 M NaCl, 5 mM b-mercaptopethanol, and
5 mM imidazole for nickel-affinity purification. Following elution in the prior buffer supplemented with 500 mM imidazole, the protein
was purified to homogeneity using size exclusion and, in some cases, cation exchange chromatography. SARS-CoV-2 RBD and S
ectodomain (S1/S2 furin cleavage site was disrupted, double proline mutations were introduced into the S2 subunit, and foldon tri-
merization motif was incorporated) were cloned into pFM1.2 with a C-terminal hexahistidine or octahistidine tag, transiently trans-
fected into Expi293F cells, and purified by cobalt-charged resin chromatography (G-Biosciences) as previously described (Alsoussi
et al., 2020).
ELISA
Purified antigens (S, RBD, or NP) were coated onto 96-well Maxisorp clear plates at 2 mg/mL in 50 mM Na2CO3pH 9.6 (70 mL) over-
night at 4C. Coating buffers were aspirated, and wells were blocked with 200 mL of 1X PBS + 0.05% Tween-20 + 1% BSA + 0.02%
NaN3 (Blocking buffer, PBSTBA) either for 1 h at 37
Cor overnight at 4C. Heat-inactivated serum samples were diluted in PBSTBA in
a separate 96-well polypropylene plate. The plates then were washed thrice with 1X PBS + 0.05% Tween-20 (PBST), followed by
addition of 50 mL of respective serum dilutions. Sera were incubated in the blocked ELISA plates for at least 1 h at room temperature.
The ELISA plates were again washed thrice in PBST, followed by addition of 50 mL of 1:2000 anti-mouse IgG-HRP (Southern Biotech
Cat. #1030-05) in PBST or 1:10000 of biotinylated anti-mouse IgG, anti-mouse IgM, or anti-mouse IgA in PBSTBA (SouthernBiotech).
Plates were incubated at room temperature for 1 h, washed thrice in PBST, and then 1:5000 dilution of streptavidin-HRP (Thermo-
Fisher) was added towells. Following a 1 h incubation at room temperature, plates werewashed thrice with PBST and 50 mL of 1-Step
Ultra TMB-ELISA was added (ThermoFisher Cat. #34028). Following a 12 to 15-min incubation, reactions were stopped with 50 mL of
2 M sulfuric acid. The absorbance of each well at 450 nmwas read (Synergy H1) within 2 min of addition of sulfuric acid. Optical den-
sity (450 nm) measurements were determined using a microplate reader (Bio-Rad). The endpoint serum dilution was calculated with
curve fit analysis of optical density (OD) values for serially diluted sera with a cut-off value set to three times the background signal.
ELISpot assay
MultiScreen-HA filter 96-well plates (Millipore) plates were pre-coated with 3 mg/ml of SARS-CoV-2 S protein overnight at 4C. After
rinsing with PBST, plates were blocked for 4 h at 37C with culture medium (RPMI, 10% FBS, penicillin-streptomycin, 1 mM sodium
pyruvate, 0.1mMnon-essential amino acids, 10mMHEPES, and 50mM b-mercaptoethanol). Single cell suspensions of splenocytes
in culture medium were added to the S protein coated plates and incubated at 37C and 5% humidified CO2 for 4 h. After washing
with PBS and PBST, plates were incubated with biotinylated anti-IgG or anti-IgA (Southern Biotech) followed by incubation with
streptavidin conjugated horseradish peroxidase (Jackson ImmunoResearch), each for 1 h at room temperature. After additional
washes with PBS, 3-amino-9-ethylcarbazole (Sigma) substrate solution was added for spot development. The reaction was stopped
by rinsing with water. Spots were counted using a Biospot plate reader (Cellular Technology).
Measurement of viral burden
SARS-CoV-2 infected mice were euthanized using a ketamine and xylazine cocktail, and organs were collected. Tissues were
weighed and homogenized with beads using a MagNA Lyser (Roche) in 1 mL of Dulbecco’s Modified Eagle’s Medium (DMEM) con-
taining 2% fetal bovine serum (FBS). RNA was extracted from clarified tissue homogenates using MagMax mirVana Total RNA isola-
tion kit (Thermo Scientific) and the KingFisher Flex extraction system (Thermo Scientific). SARS-CoV-2 RNA levels were measured
by one-step quantitative reverse transcriptase PCR (qRT-PCR) TaqMan assay as described previously (Hassan et al., 2020). SARS-
CoV-2 nucleocapsid (N) and Open Reading Frame 1a (ORF1a) specific primers and probe sets were used: (N: F Primer: ATGCTG
CAATCGTGCTACAA; R primer: GACTGCCGCCTCTGCTC; probe: /56-FAM/TCAAGGAAC/ZEN/AACATTGCCAA/3IABkFQ/;
ORF1a: F Primer: TTCAGTTGACTTCGCAGTGG; R primer: GGACGGGTTTGAGTTTTTCA; probe: /56-FAM/AACTAACAT/ZEN/
CTTTGGCACTGTTT/3IABkFQ) (Integrated DNA Technologies). Viral RNA was expressed as (N) or (ORF1a) gene copy numbers
per milligram on a log10 scale. For some samples, viral titer was determined by plaque assay on Vero E6 cells.
Cytokine and chemokine mRNA measurements
RNA extracted from lung homogenates was DNase-treated and used to synthesize cDNA using the High-Capacity cDNA Reverse
Transcription kit (Thermo Scientific) with the addition of RNase inhibitor according to the manufacturer’s protocol. Cytokine and
chemokine expression was determined using TaqMan Fast Universal PCR master mix (Thermo Scientific) with commercial
primers/probe sets specific for IFN-g (IDT: Mm.PT.58.41769240), IL-6 (Mm.PT.58.10005566), IL-1b (Mm.PT.58.41616450), CXCL10
(Mm.PT.58.43575827), CCL2 (Mm.PT.58.42151692), CCL5 (Mm.PT.58.43548565), CXCL11 (Mm.PT.58.10773148.g), IFN-b
(Mm.PT.58.30132453.g), and IFNl2/3 (Thermo Scientific Mm04204156_gH) and results were normalized to GAPDH (Mm.PT.39a.1)
levels. Fold change was determined using the 2-DDCt method comparing treated mice to naive controls.
Plaque assay
Vero-Furin cells were seeded in 12-well plates one day prior to inoculation. Lung homogenates were serially diluted in DMEM sup-
plemented with 2% FBS, HEPES, and penicillin-streptomycin and incubated on cells for 1 hr at 37C. After 1 h incubation, cells wereCell 183, 169–184.e1–e6, October 1, 2020 e5
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plates were fixed with 4% PFA for 20 min at room temperature. After removal of PFA, plates were stained with 0.05% (w/v) crystal
violet in 20%methanol for 10-20 min. Crystal violet was removed, and plates were rinsed with water or PBS. Plaques were counted
manually to determine infectious virus titer.
Peptide restimulation and intracellular cytokine staining
Splenocytes from intramuscularly vaccinated mice were incubated in culture with a pool of 253 overlapping 15-mer SARS-CoV-2 S
peptides (Grifoni et al., 2020) for 12 h at 37C before a 4 h treatment with brefeldin A (BioLegend, 420601). Following blocking with
FcgR antibody (BioLegend, clone 93), cells were stained on ice with CD45 BUV395 (BD BioSciences clone 30-F11); CD44 PE-Cy7,
CD4 PE-Cy5, CD8b PreCP-Cy5.5, and CD19 APC-Cy7 (BioLegend clones, IM7, GK1.5, YTS156.7.7, and 6D5, respectively), and
Fixable Aqua Dead Cell Stain (Invitrogen, L34966). Stained cells were fixed and permeabilized with the Foxp3/Transcription Factor
Staining Buffer Set (eBiosciences, 00-5523). Subsequently, intracellular staining was performed with anti-IFN-g Alexa 647 (BD Bio-
sciences, clone XMG1.2), anti-TNFa BV605 (BioLegend, clone MP6-XT22), and anti-GrB PE (Invitrogen, GRB04). Lungs from immu-
nized mice were harvested and digested for 1 h at 37C in digestion buffer consisting of RPMI media supplemented with (167 mg/ml)
of Liberase DH (Sigma) and (100 mg/ml) of DNase I (Sigma). Lung cells were incubated at 37C with the pool of 253 overlapping 15-
mer SARS-CoV-2 S peptides described above in the presence of brefeldin A for 5 h at 37C. Lung cells then were stained as
described above except that CD4-BV421 (BioLegend clone GK1.5) replaced the CD4-PE-Cy5, no CD19 staining was included,
and CD103-FITC and CD69-BV711 (BioLegend clones, 2E7, and, H1.2F3, respectively) were added. Analysis was performed on a
BD LSRFortessa X-20 cytometer, using FlowJo X 10.0 software.
Flow cytometry-based antigen characterization
HEK293T cells were seeded at 106 cells/well in 6-well plates 24 h prior to transduction with ChAd-SARS-CoV-2-S (MOI of 5). After 20
h, cells were harvested, fixed and permeabilized using Foxp3 Transcription Factor Staining Buffer Set (Thermo Fisher), and stained
for viral antigen after incubation with the following anti-SARS-CoV-2 neutralizing murine mAbs: SARS2-01, SARS2-02, SARS2-07,
SARS2-11, SARS2-12, SARS2-16, SARS2-18, SARS2-20, SARS2-21, SARS2-22, SARS2-23, SARS2-29, SARS2-31, SARS2-32,
SARS2-34, SARS2-38, SARS2-39, SARS2-50, SARS2-55, SARS2-58, SARS2-66, and SARS2-71 (L.A.V. and M.S.D., unpublished
data). H77.39 (Sabo et al., 2011), an isotype-matched anti-HCV E2 mAb was used as a negative control. Cells were washed, incu-
bated with Alexa Fluor 647 conjugated goat anti-mouse IgG (Thermo Fisher), and analyzed by flow cytometry using a MACSQuant
Analyzer 10 (Miltenyi Biotec). The percentage of cells positive for a given mAb was compared with cells stained with a saturating
amount of an oligoclonal mixture of anti-SARS-CoV-2 mAbs.
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical significance was assigned when P values were < 0.05 using Prism Version 8 (GraphPad). Tests, number of animals (n),
median values, and statistical comparison groups are indicated in the Figure legends. Analysis of anti-S, anti-RBD, neutralization ti-
ters, and ELISPOT values in mice after vaccination was performed using aMann-Whitney test. Differences in viral titers or chemokine
and cytokine levels after SARS-CoV-2 infection of immunized mice were determined using a Mann-Whitney test. Anti-nucleoprotein
antibody levels were compared using a paired t test.e6 Cell 183, 169–184.e1–e6, October 1, 2020
Supplemental Figures
Figure S1. ChAd-SARS-CoV-2-S Vaccine Induces Neutralizing Antibodies as Measured by FRNT, Related to Figure 1
Four-week old female BALB/c mice were primed or primed and boosted with ChAd-control or ChAd-SARS-CoV-2-S via intramuscular route. A-B. Serum
samples fromChAd-control or ChAd-SARS-CoV-2 vaccinated mice were collected at day 21 after priming (A) or boosting (B) and assayed for neutralizing activity
by FRNT. Serum neutralization curves corresponding to individual mice are shown for the indicated vaccines (n = 15-30 per group). Each point represents the
mean of two technical replicates. (C). An ELISA measured anti-SARS-CoV-2 NP IgG responses in paired sera obtained 5 days before and 8 days after SARS-
CoV-2 challenge of ChAd-control or ChAd-SARS-CoV-2-S mice vaccinated by an intramuscular route (n = 5: **p < 0.01; ***p < 0.001; paired t test). Dotted lines
represent the mean IgG titers from naive sera.
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Figure S2. Gating Strategy for Analyzing T Cell Responses, Related to Figure 1
Four-week old female BALB/cmice were immunizedwith ChAd-control or ChAd-SARS-CoV-2-S and boosted four weeks later. T cell responseswere analyzed in
splenocytes at day 7 post-boost. Cells were gated for lymphocytes (FSC-A/SSC-A), singlets (SSC-W/SSC-H), live cells (Aqua-), CD45+, CD19- followed by CD4+
or CD8+ cell populations expressing IFNg or granzyme B.
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Figure S3. Impact of Pre-existing ChAd Immunity on Transduction of Mice with Hu-AdV5-hACE2, Related to Figures 1 and 2
Four-week old female BALB/c mice were primed or primed and boosted. Serum samples were collected one day prior to Hu-AdV5-hACE2 transduction.
Neutralizing activity of Hu-AdV5-hACE2 in the sera from the indicated vaccine groups was determined by FRNT after prime only (A) or prime and boost (B). Each
symbol represents a single animal; each point represents two technical repeats and bars indicate the range. A positive control (anti-Hu-Adv5 serum) is included as
a frame of reference.
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(legend on next page)
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Figure S4. Intranasal Inoculation of ChAd-SARS-CoV-2-S Induces Neutralizing Antibodies as Measured by FRNT and Protects against
SARS-CoV-2 Replication, Related to Figures 4 and 5
Five-week old female BALB/cmicewere immunizedwith ChAd-control or ChAd-SARS-CoV-2-S via an intranasal inoculation route. Serum samples collected one
month after immunization were assayed for neutralizing activity by FRNT. Mice were boosted at day 30 after priming and were sacrificed one week later to
evaluate immune responses. (A) Serum samples from ChAd-control or ChAd-SARS-CoV-2-S vaccinated mice were tested for neutralizing activity with SARS-
CoV-2 strain 2019 n-CoV/USA_WA1/2020 (n = 8-10 per group). (B) Serum samples from ChAd-SARS-CoV-2-S vaccinated mice were tested for neutralization of
recombinant luciferase-expressing SARS-CoV-2 viruses (wild-type (left) and D614G variant (middle)). (Right) Paired EC50 values are indicated (n = 5; n.s. not
significant, paired t test). (C) BAL fluid was collected from ChAd-control or ChAd-SARS-CoV-2-S vaccinated mice, and neutralization of SARS-CoV-2 strain 2019
n-CoV/USA_WA1/2020 was measured using a FRNT assay (n = 8-10 per group). Each point represents the mean of two technical replicates. (D) On day 35
post-immunization, mice were challenged via intranasal route with 4 3 105 FFU of SARS-CoV-2 five days after Hu-AdV5-hACE2 transduction and anti-Ifnar1
mAb treatment as described in Figure 2. Tissues were collected at 4 dpi for viral burden measurements. Genomic RNA (ORF1a) levels were determined in




Figure S5. SARS-CoV-2 NP-Specific IgM and IgG Antibody Responses following SARS-CoV-2 Challenge, Related to Figure 5
Five-week-old BALB/c female mice were immunized with ChAd-control or ChAd-SARS-CoV-2-S via an intranasal route. One month later, mice were transduced
with Hu-AdV5-ACE2 and challenged with SARS-CoV-2 as described in Figure 5. An ELISAmeasured anti-SARS-CoV-2 NP IgM and IgG responses in paired sera
obtained 5 days before and 8 days after SARS-CoV-2 challenge. Serum ELISA curves corresponding to individual mice are shown for the indicated vaccines or
control naive BALB/c mice (n = 6 per group).
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Figure S6. Intranasal Inoculation of ChAd-SARS-CoV-2-S Induces Neutralizing Antibodies in K18-hACE2 Mice, Related to Figure 6
Four-week old female K18-hACE2 mice were immunized with ChAd-control or ChAd-SARS-CoV-2-S via an intranasal inoculation route. Serum samples
collected four weeks after immunization were assayed for neutralizing activity by FRNT (n = 7 per group). Each point represents the mean of two technical
replicates.
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